[go: up one dir, main page]

BR0315777A - Uso de derivados de piperazina como antagonistas ccr1 - Google Patents

Uso de derivados de piperazina como antagonistas ccr1

Info

Publication number
BR0315777A
BR0315777A BR0315777-6A BR0315777A BR0315777A BR 0315777 A BR0315777 A BR 0315777A BR 0315777 A BR0315777 A BR 0315777A BR 0315777 A BR0315777 A BR 0315777A
Authority
BR
Brazil
Prior art keywords
piperazine derivatives
present
ccr1
ccr1 antagonists
directed
Prior art date
Application number
BR0315777-6A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Anderson See Gaweco
Ronald Paul Gladue
Matthew Merrill Hayward
Greg Dean Lundquist
Christopher Stanley Poss
Andre Shavnya
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0315777A publication Critical patent/BR0315777A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

"USO DE DERIVADOS DE PIPERAZINA COMO ANTAGONISTAS CCR1". A presente invenção refere-se com, o composto de fórmula I" e as suas formas farmaceuticamente aceitáveis; em que X, Y, a, b, c, d, R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬ e R¬ 5¬ são como aqui definidos. Além disso, a presente invenção é também dirigida a formulações farmacêuticas compreendendo um composto de fórmula 1 e um veículo farmaceuticamente aceitável. Adicionalmente, a presente invenção é dirigida a métodos de utilização dos compostos e formulações aqui descritos para o tratamento ou prevenção de uma doença ou patologia que possa ser tratada ou prevenida por antagonização de receptores CCR1 em um mamífero.
BR0315777-6A 2002-10-30 2003-10-20 Uso de derivados de piperazina como antagonistas ccr1 BR0315777A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42259002P 2002-10-30 2002-10-30
PCT/IB2003/004612 WO2004039376A1 (en) 2002-10-30 2003-10-20 Use of piperazine derivatives as ccr1 antagonists

Publications (1)

Publication Number Publication Date
BR0315777A true BR0315777A (pt) 2005-09-13

Family

ID=32230375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315777-6A BR0315777A (pt) 2002-10-30 2003-10-20 Uso de derivados de piperazina como antagonistas ccr1

Country Status (8)

Country Link
US (1) US20040092529A1 (pt)
EP (1) EP1583533A1 (pt)
JP (1) JP2006506391A (pt)
AU (1) AU2003269364A1 (pt)
BR (1) BR0315777A (pt)
CA (1) CA2498261A1 (pt)
MX (1) MXPA05004650A (pt)
WO (1) WO2004039376A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080089453A (ko) * 2006-01-25 2008-10-06 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
TW200821316A (en) * 2006-07-19 2008-05-16 Astrazeneca Ab Novel compounds 243
FR2953356B1 (fr) 2009-11-30 2014-12-05 Commissariat Energie Atomique Processeur de traitement de donnees numeriques a operateur papillon pour l'execution d'une fft/ifft et terminal de telecommunication
TW201130810A (en) 2009-12-23 2011-09-16 Ironwood Pharmaceuticals Inc CRTH2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2013024028A1 (en) * 2011-08-12 2013-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and compositions for treating proteinopathies
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
US10882834B2 (en) 2013-09-20 2021-01-05 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CN104262291A (zh) * 2014-09-22 2015-01-07 山东理工大学 双-(对卤苯基)甲基哌嗪缩乙酸的合成方法
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CA3059458A1 (en) * 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
RU2681012C1 (ru) * 2018-05-07 2019-03-01 Акционерное общество "Центральное конструкторское бюро "Монолит" Способ укрепления слабого донного грунта в условиях ледового покрытия акватории
WO2023141467A2 (en) * 2022-01-18 2023-07-27 University Of Kentucky Research Foundation Compositions, methods, and development of arid4b inhibitors
CN115350191B (zh) * 2022-09-23 2023-08-18 温州医科大学 一种试剂bx-471的新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IL151923A0 (en) * 2000-03-31 2003-04-10 Pfizer Prod Inc Novel piperazine derivatives
AP2004003008A0 (en) * 2001-10-22 2004-06-30 Pfizer Prod Inc Piperazine derivatives with CCR1 receptor antagonist activity

Also Published As

Publication number Publication date
MXPA05004650A (es) 2005-06-08
JP2006506391A (ja) 2006-02-23
CA2498261A1 (en) 2004-05-13
AU2003269364A1 (en) 2004-05-25
US20040092529A1 (en) 2004-05-13
EP1583533A1 (en) 2005-10-12
WO2004039376A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0213452A (pt) Derivados de piperazina com atividade antagonista receptora de ccr1
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
BR0315580A (pt) Derivados de metileno uréia
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
SE0100567D0 (sv) Compounds
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
GB0112348D0 (en) Compounds
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
DE60001586D1 (de) Diphenyl-piperidin derivate
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
BR0315837A (pt) Derivados de amida de ácido heteroaril-hexanóico como agentes imunomoduladores

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired